SCHEDULE 13D: ARCH Venture Funds Disclose Significant 25.5% Stake in Metsera, Inc. Following IPO

ARCH Venture Funds and affiliated entities have disclosed a substantial beneficial ownership of 25.5% in Metsera, Inc. common stock, acquired through a series of preferred stock conversions and recent IPO purchases for investment purposes.

Summary

• ARCH Venture Fund XII, L.P. (AVF XII) and ARCH Venture Fund XIII, L.P. (AVF XIII), along with their general partners and investment committee members, collectively reported beneficial ownership of 26,816,808 shares of Metsera, Inc. common stock.
• This represents 25.5% of Metsera, Inc.'s outstanding common stock, based on 105,326,848 shares outstanding after underwriters' allotment.
• Kristina Burow beneficially owns 26,829,220 shares (25.5%), including 12,412 shares from exercisable options.
• Paul Berns beneficially owns 9,289,858 shares (8.8%), including 976,178 shares held directly and 18,619 shares from exercisable options.
• The shares were acquired for investment purposes, with the reporting persons stating they may dispose of or acquire additional shares depending on market conditions and the Issuer's prospects.
• The total amount paid for securities by AVF XII was $39,280,029.84 and by AVF XIII was $72,719,961.84.
• The acquisitions included 6,383,731 Series A Preferred shares purchased by AVF XIII on August 26, 2024, at $7.0492 per share, and 1,139,951 Series B Preferred shares purchased by each of AVF XII and AVF XIII on November 12, 2024, at $11.8426 per share, all of which converted to common stock at the IPO.
• Additionally, on February 3, 2025, AVF XII purchased 1,432,224 common shares and AVF XIII purchased 789,998 common shares from IPO underwriters at $18.00 per share.

Sentiment

Score: 7

Explanation: The filing indicates a significant, long-term investment by a reputable venture capital firm in Metsera, Inc. post-IPO, which is generally a positive signal of investor confidence. The lock-up agreement is standard for IPO investors and not inherently negative, as it prevents immediate selling pressure from major shareholders.

Positives

• Significant investment by a prominent venture capital firm (ARCH Venture) indicates confidence in Metsera, Inc.'s long-term prospects.
• The acquisition of shares through preferred stock conversions and recent IPO purchases demonstrates a multi-stage and substantial commitment to the company.
• The Investors' Rights Agreement provides ARCH Venture funds with certain registration rights (demand, piggyback, and Form S-3), offering a potential pathway for future liquidity.

Negatives

• The lock-up agreement restricts the sale of a significant portion of the common stock held by AVF XII, AVF XIII, Kristina Burow, and Paul Berns for 180 days after February 3, 2025, limiting immediate liquidity for these reporting persons.

Risks

• The reporting persons may dispose of or acquire additional shares of Metsera, Inc. common stock in the future, which could impact market conditions and the company's share price.
• The value of the investment is subject to the business and prospects of Metsera, Inc. and other general market factors.

Future Outlook

The reporting persons acquired the common stock for investment purposes and may, depending on market conditions, the continuing evaluation of Metsera, Inc.'s business and prospects, and other factors, dispose of or acquire additional shares of common stock.

Industry Context

This Schedule 13D filing indicates a significant post-IPO investment by a major venture capital firm, ARCH Venture, in Metsera, Inc. This suggests continued investor confidence in the biotechnology or pharmaceutical sector, particularly in companies that have recently gone public. Such substantial stakes by institutional investors are common in the early stages of publicly traded life sciences companies, providing capital and often strategic guidance.

Corporate Governance

Stakeholder Impact

• Shareholders: The significant stake held by ARCH Venture funds could be seen as a vote of confidence in Metsera, Inc., potentially stabilizing or supporting the share price. The lock-up agreement prevents immediate large-scale selling by these major investors.
• Company (Metsera, Inc.): The substantial investment provides capital and validates the company's prospects, potentially aiding future financing or strategic partnerships.

Next Steps

• The reporting persons may dispose of or acquire additional shares of Metsera, Inc. common stock in the future, depending on market conditions and the Issuer's performance.
• The lock-up agreement restricts the sale of shares by the reporting persons until approximately August 2, 2025 (180 days after February 3, 2025).
• The registration rights granted to AVF XII and AVF XIII will terminate upon the earliest of Rule 144 eligibility, a deemed liquidation event, or the fifth anniversary of the IPO.

Key Dates

Keywords

Metsera Inc., ARCH Venture Fund XII, ARCH Venture Fund XIII, Schedule 13D, SEC filing, beneficial ownership, common stock, IPO, investment, venture capital, registration rights, lock-up agreement, institutional investor